Aberrant DNA methylation patterns are a characteristic feature of cancer including myeloid malignancies such as acute myeloid leukemia (AML). The mechanisms behind aberrant DNA methylation have ...

BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...

The changes cement the importance of TNG462 to the company’s prospects. Tango is testing the PRMT5 inhibitor in a phase 1/2 trial that is due to deliver data in the second half of the year.

TNG462 is a potential best-in-class PRMT5 inhibitor being developed to treat pancreatic and lung cancer. When will data from the TNG462 Phase 1/2 trial be released? A clinical data update from the ...

For example, DNA methylation modifies gene expression without altering the nucleotide sequence. A well-studied DNA methylation-based phenomenon is genomic imprinting (ie, genotype-independent ...

Top of the list is PRMT5/MTA inhibitor MRTX1719, which BMS said could be a first-in-class therapy for cancers with MTAP deletions seen in around 10% of all cancers, including NSCLC, as well as ...

The cuts are "in light of the extremely challenging financial markets" and the biotech's "strong conviction in the value of our clinical programs," which include two PRMT5 inhibitor cancer candidates.

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade glioma and uveal melanoma, that Pathos AI acquired from Prelude Therapeutics ...

Scientists have found that global warming in the Middle East and North Africa is making breast, ovarian, uterine, and cervical cancers more common and more deadly. The rise in rates is small but ...

Protein arginine methylation is an epigenetic modification function not only in transcription, RNA processing, and signal transduction cascades, but also in many cancer-immunity cycle processes.